二甲雙胍市場規模、佔有率和成長分析：按劑型、適應症、通路、最終用戶、產品和地區分類－2026-2033年產業預測

2024 年全球二甲雙胍市場價值為 35.2 億美元，預計到 2033 年將從 2025 年的 37 億美元成長至 55.2 億美元，在預測期（2026-2033 年）內複合年成長率為 5.12%。

二甲雙胍仍是全球醫藥市場的基石，尤其是在面臨生活方式改變和人口老化等問題的發展中地區，這些地區的第2型糖尿病盛行率正在不斷上升。二甲雙胍作為第一線治療藥物的地位，體現了其療效、安全性和可負擔性，這些優勢推動了其廣泛應用。該藥物的多功能性也使其應用於預防糖尿病前期和治療卵巢症候群，進一步刺激了市場需求。將二甲雙胍與SGLT-2抑制劑和GLP-1促效劑等藥物合併使用，這種聯合治療因其能夠改善患者療效和提高成本效益，對保險公司和醫療服務提供者都極具吸引力。人工智慧驅動的藥物依從性監測技術的引入，透過提高患者參與度和改善治療依從性，正在重塑市場格局，進而影響著製造商的產品開發和分銷策略。

全球二甲雙胍市場的成長要素

全球第2型糖尿病盛行率的不斷上升，顯著推動了對二甲雙胍的需求，二甲雙胍是一種廣為人知的首選口服治療藥物。其療效、安全性和可負擔性使其成為醫療專業人員的首選，鞏固了其在治療方案中的地位。意識提升和預防性醫療保健措施的開展，促進了早期診斷，擴大了適合二甲雙胍治療的患者群體，進一步推動了市場成長。此外，獲得監管機構批准納入國家藥品目錄，提高了二甲雙胍在各種醫療機構的可及性，進一步加速了全球二甲雙胍市場的發展。

全球二甲雙胍市場的限制因素

由於監管機構對二甲雙胍的安全性進行嚴格審查，全球二甲雙胍市場面臨許多限制。對罕見乳酸性酸中毒的擔憂以及腎功能不全患者的禁忌症，使得嚴格的標籤要求和持續的安全性評估成為必要。這些規定可能會阻礙產品及時上市並限制市場推廣活動。此外，醫療專業人員在開立二甲雙胍處方時通常較為謹慎，尤其是在高風險族群中，這可能導致其使用率較低。如此嚴格的審查要求生產商投入更多資源用於合規措施，這可能會限制市場成長機會。

全球二甲雙胍市場趨勢

在全球糖尿病精準醫療趨勢日益成長的推動下，二甲雙胍市場正經歷著顯著的變化。隨著個人化醫療的普及，二甲雙胍的使用方式也正在改變。醫療專業人員正利用藥物遺傳學數據來調整劑量並最佳化治療方案，以更好地適應每位患者的個別情況。這種方法不僅提高了療效，還最大限度地減少了胃腸道併發症等副作用，從而促進了包括緩釋製劑在內的新劑型的研發。因此，二甲雙胍已從主流的第一線治療藥物發展成為個人化糖尿病管理的關鍵組成部分，其應用範圍不斷擴大，並提高了全球各醫療體系中患者的用藥依從性。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球二甲雙胍市場規模：依劑型分類。

• 速釋製劑（IR）
• 緩釋製劑（XR/ER）

全球二甲雙胍市場規模：依適應症分類

• 2型糖尿病
• 糖尿病前期
• 卵巢症候群（PCOS）

全球二甲雙胍市場規模：按分銷管道分類

• 零售藥房
• 醫院藥房
• 線上

全球二甲雙胍市場規模：依最終用戶分類

• 老年患者
• 成人
• 青春期

全球二甲雙胍市場規模：依產品分類

• 品牌商品（二甲雙胍）
• 學名藥

全球二甲雙胍市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Merck KGaA（Glucophage-historical）
• Teva Pharmaceutical
• Mylan（Viatris）
• Sun Pharmaceutical
• Dr. Reddy's Laboratories
• Cipla Ltd.
• Lupin Limited
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals
• Aurobindo Pharma
• Glenmark Pharmaceuticals
• Zydus Cadila
• Wockhardt Ltd.
• Torrent Pharmaceuticals
• Sandoz（Novartis）
• Apotex Inc.
• Perrigo Company
• Alkem Laboratories
• IPCA Laboratories
• Strides Pharma Science

結論與建議

Global Metformin Market size was valued at USD 3.52 Billion in 2024 and is poised to grow from USD 3.7 Billion in 2025 to USD 5.52 Billion by 2033, growing at a CAGR of 5.12% during the forecast period (2026-2033).

Metformin remains a cornerstone of the global pharmaceutical landscape, driven by the increasing prevalence of type-2 diabetes, particularly in developing regions facing lifestyle changes and ageing demographics. Its emergence as a first-line therapy illustrates its effectiveness, safety, and affordability, which have catalyzed widespread adoption. The drug's versatility extends to its use in preventing pre-diabetes and managing polycystic ovary syndrome, further fueling demand. The trend toward combination therapies, where metformin is paired with agents like SGLT-2 inhibitors and GLP-1 agonists, enhances patient outcomes and cost efficiency, appealing to insurers and healthcare providers alike. The integration of AI-driven adherence monitoring technologies is refining the market by promoting patient engagement and improving treatment compliance, thus reshaping product development and distribution strategies for manufacturers.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Metformin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Metformin Market Segments Analysis

Global metformin market is segmented by formulation, indication, distribution, end-user, product and region. Based on formulation, the market is segmented into Immediate Release (IR) and Extended Release (XR/ER). Based on indication, the market is segmented into Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome (PCOS). Based on distribution, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online. Based on end-user, the market is segmented into Elderly Patients, Adults and Adolescents. Based on product, the market is segmented into Branded (Glucophage) and Generics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Metformin Market

The rising incidence of type 2 diabetes across the globe significantly drives the demand for metformin, widely recognized as the first-line oral therapy. Its effectiveness, safety, and affordability make it a preferred choice among healthcare professionals, solidifying its role in treatment protocols. Efforts to increase patient awareness and preventive health measures encourage earlier diagnoses, expanding the pool of individuals suitable for metformin treatment and further bolstering market growth. Additionally, endorsements from regulatory agencies for its inclusion in national medication lists improve its availability in various healthcare environments, further promoting the global metformin market's development.

Restraints in the Global Metformin Market

The global market for metformin faces several restraints due to the rigorous oversight by regulatory agencies regarding the drug's safety profile. Concerns about infrequent occurrences of lactic acidosis and its contraindications in patients with renal impairment result in strict labeling mandates and ongoing safety evaluations. These regulations can hinder timely product introductions and restrict marketing efforts. Additionally, healthcare professionals often approach prescribing metformin with caution, particularly for high-risk groups, which can lead to decreased utilization. This level of scrutiny necessitates that manufacturers invest more resources into compliance efforts, potentially limiting growth opportunities within the market.

Market Trends of the Global Metformin Market

The Global Metformin market is experiencing a notable transformation driven by the rising trend of precision diabetes care. The increasing incorporation of personalized medicine is reshaping metformin usage, with healthcare providers leveraging pharmacogenomic data to customize dosing and optimize treatment regimens tailored to individual patient profiles. This approach not only enhances treatment efficacy but also minimizes adverse effects like gastrointestinal intolerance, prompting the development of novel formulations, including extended-release options. As a result, metformin is evolving from a mainstream first-line therapy to a pivotal player in bespoke diabetes management, broadening its reach and improving patient adherence in various healthcare systems globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Metformin Market Size by Formulation & CAGR (2026-2033)

• Market Overview
• Immediate Release (IR)
• Extended Release (XR/ER)

Global Metformin Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Type 2 Diabetes
• Prediabetes
• Polycystic Ovary Syndrome (PCOS)

Global Metformin Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Retail Pharmacies
• Hospital Pharmacies
• Online

Global Metformin Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Elderly Patients
• Adults
• Adolescents

Global Metformin Market Size by Product & CAGR (2026-2033)

• Market Overview
• Branded (Glucophage)
• Generics

Global Metformin Market Size & CAGR (2026-2033)

• North America (Formulation, Indication, Distribution, End-User, Product)
  • US
  • Canada
• Europe (Formulation, Indication, Distribution, End-User, Product)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Formulation, Indication, Distribution, End-User, Product)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Formulation, Indication, Distribution, End-User, Product)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Formulation, Indication, Distribution, End-User, Product)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck KGaA (Glucophage - historical)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perrigo Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IPCA Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strides Pharma Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations